Abstract:Abstract The N-nitrosamine, N-nitrosodimethylamine (NDMA), is an environmental mutagen and rodent carcinogen. Small levels of NDMA have been identified as an impurity in some commonly used drugs, resulting in several product recalls. In this study, NDMA was evaluated in an OECD TG-488 compliant MutaTMMouse gene mutation assay (28-day oral dosing across seven daily doses of 0.02-4 mg/kg/day) using an integrated design that assessed mutation at the transgenic lacZ locus in various tissues and at the endogenous Pig-a gene-locus, along with micronucleus frequencies in peripheral blood. Liver pathology was determined together with NDMA exposure in blood and liver. The additivity of mutation induction was assessed by including two acute single-dose treatment groups (i.e. 5 and 10 mg/kg dose on Day 1), which represented the same total dose as two of the repeat dose treatment groups. NDMA did not induce statistically significant increases in mean lacZ mutant frequency (MF) in bone marrow, spleen, bladder, or stomach, nor in peripheral blood (Pig-a mutation or micronucleus induction) when tested up to 4 mg/kg/day. There were dose-dependent increases in mean lacZ MF in the liver, lung, and kidney following 28-day repeat dosing or in the liver and kidney after a single dose (10 mg/kg). No observed genotoxic effect levels (NOGEL) were determined for the positive repeat dose–response relationships. Mutagenicity did not exhibit simple additivity in the liver since there was a reduction in MF following NDMA repeat dosing compared with acute dosing for the same total dose. Benchmark dose modelling was used to estimate point of departure doses for NDMA mutagenicity in MutaTMMouse and rank order target organ tissue sensitivity (liver > kidney or lung). The BMD50 value for liver was 0.32 mg/kg/day following repeat dosing (confidence interval 0.21–0.46 mg/kg/day). In addition, liver toxicity was observed at doses of ≥ 1.1 mg/kg/day NDMA and correlated with systemic and target organ exposure. The integration of these results and their implications for risk assessment are discussed.

In vivo genotoxicity assessment of N‐(‐9 acridinyl)‐b‐alanine hydrochloride (S‐300) using a validated Pig‐a mutagenesis assay

Toxicologic Evaluation of Repetitive 4-Week Intravenous Injections of Midkine Antisense Oligonucleotide Nanoliposomes in Rats

Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione

Application of the in Vivo Pig-a Gene Mutation Assay to Test the Potential Genotoxicity of P-Phenylenediamine.

Assessment of the Pig-a, micronucleus, and comet assay endpoints in rats treated by acute or repeated dosing protocols with procarbazine hydrochloride and ethyl carbamate.

The in Vivo Pig-a Gene Mutation Assay is Applied to Study the Genotoxicity of Procarbazine Hydrochloride in Sprague-Dawley Rats

[Genotoxicity Assessment of 2-Ethylhexyl Acrylate Using an in Vivo Pig-a Gene Mutation Assay Integrated System].

Assessment of genotoxicity induced by sodium selenite using the in vivo Pig-a gene mutation assay

Assessment of Pig-a, Micronucleus and Comet Assay Endpoints in Tg.RasH2 Mice Carcinogenicity Study of Aristolochic Acid I.

The PIG-A gene mutation assay in human biomonitoring and disease

The Potential Application of Human PIG‐A Assay on Azathioprine‐treated Inflammatory Bowel Disease Patients

A Population Study Using The Human Erythrocyte Pig-A Assay

Toxicity of a Novel Anti-Tumor Agent 20(S)-Ginsenoside Rg3: A 26-Week Intramuscular Repeated Administration Study in Beagle Dogs

Assessment of the Genotoxicity of 2-Methylfuran Based on a Multi-Endpoint Genotoxicity Test System in Vivo

Acute and sub-acute oral toxicological evaluations and mutagenicity of N-carbamylglutamate (NCG)

[Optimization Ofpig-Agene Mutation in Rats and Assessment of Time-dependent and Dose-response Relationship of N-ethyl-N-nitrosourea].

N-Nitrosodimethylamine investigations in MutaTMMouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations

BIO 300: A Prophylactic Radiation Countermeasure for Acute Radiation Syndrome

Differential genotoxicity of Polygoni Multiflori in rat and human: insights from Ames test and S9 metabolic activation system

Quantitative Bioanalytical LC-MS/MS Assay for S130 in Rat Plasma-Application to a Pharmacokinetic Study.

Assessing the genotoxicity of N‐nitrosodiethylamine with three in vivo endpoints in male Big Blue® transgenic and wild‐type C57BL/6N mice